Clinical Trials Browser

INDUSTRY × Has results × dalotuzumab × Clear all

NCT01609231 2020-05-04

MK-0646-025

Phase 2 Terminated

11 enrolled 8 charts

Gastrointestinal

Rectal Neoplasms

NCT01605396 2019-03-25

MK-8669-064

Phase 2 Completed

80 enrolled 13 charts

Breast Neoplasms

NCT00635778 2018-10-09

MK-0646-002

Phase 1 Completed

50 enrolled 32 charts

Other solid neoplasm

Advanced Solid Tumors

NCT01243762 2018-08-16

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Phase 1 Terminated

47 enrolled 12 charts

GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT00759785 2018-08-15

MK-0646-013

Phase 1 Completed

48 enrolled 10 charts

Breast Neoplasms

NCT00925015 2018-08-15

Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)

Phase 1 Completed

20 enrolled 30 charts

Gastrointestinal

Colorectal Neoplasms

NCT00614393 2018-08-08

Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)

Phase 2 Completed

558 enrolled 17 charts

Gastrointestinal

Colorectal Neoplasms

NCT00694356 2018-08-08

Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)

Phase 1 Completed

15 enrolled 13 charts

Neoplasms

NCT00701103 2018-08-08

Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)

Phase 1 Completed

80 enrolled 23 charts

Multiple Myeloma